NCT02216552 - Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents | Biotech Hunter

Enrollment

10

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

January 1, 2017

Study Completion Date

March 20, 2017

Conditions

NAFLDTYPE 2 DIABETESMETABOLIC SYNDROME

Interventions

DIETARY_SUPPLEMENT

Resveratrol

All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.

DIETARY_SUPPLEMENT

Placebo

All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.

Trial Locations (1)

R3E 3P4

Children's Hospital Research Institute of Manitoba/University of Manitoba, Winnipeg